Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18735209 | METHOD FOR SELECTING AEROBIC DENITRIFYING FUNGUS AND METHOD FOR REMEDIATING WATER BODY WITH LOW CARBON-TO-NITROGEN RATIO USING AEROBIC DENITRIFYING FUNGUS | June 2024 | February 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18631515 | PROCESS FOR CONTROLLING ORGANIC ACID RATIOS IN A CARBON DIOXIDE BIOCONVERSION PROCESS | April 2024 | May 2025 | Allow | 13 | 1 | 0 | No | No |
| 18532631 | METHOD FOR PREPARING ACTIVE PROTEIN PEPTIDE AND PREPARED ACTIVE PROTEIN PEPTIDE AND USE THEREOF | December 2023 | September 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18508109 | METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS | November 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18286791 | PROCESS TO PRODUCE MONO-RHAMNOLIPIDS | October 2023 | January 2025 | Allow | 15 | 4 | 0 | No | No |
| 18237027 | FERROUS PEBBLES AS A CATALYST FOR ENHANCED METHANE GENERATION FROM RICE HUSK | August 2023 | November 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18451977 | BONE GRAFTS INCLUDING OSTEOGENIC STEM CELLS, AND METHODS RELATING TO THE SAME | August 2023 | July 2024 | Allow | 11 | 1 | 0 | No | No |
| 18351696 | ENGINEERED MIGRASOME, METHOD FOR PREPARING SAME, AND USES THEREOF | July 2023 | September 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18035938 | METHOD FOR DETECTING ORGANOPHOSPHORUS PESTICIDE BY MICROFLUIDIC CHIP BASED ON FLUORESCENT SENSING FILM | May 2023 | February 2025 | Allow | 22 | 1 | 0 | No | No |
| 18295384 | DEVICE AND METHOD FOR CONTROLLING A BIOREACTOR | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18026593 | METHOD FOR PRODUCING BIOGAS FROM WASTE LIQUID/RESIDUE AFTER DIOSGENIN EXTRACTION FROM DIOSCOREA COMPOSITA BY ALUMINUM CHLORIDE | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18119339 | SYSTEM AND METHODS FOR MULTIPLEXED ANALYSIS OF CELLULAR AND OTHER IMMUNOTHERAPEUTICS | March 2023 | November 2024 | Allow | 20 | 0 | 1 | No | No |
| 18170196 | SCREENING METHOD | February 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18110861 | APPARATUS AND METHOD OF USING A SIMULATED SKIN SUBSTRATE FOR TESTING INSECT REPELLANTS | February 2023 | December 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 18108849 | METHOD FOR ASSESSING VALIDITY OF CELL THERAPY PRODUCT | February 2023 | January 2025 | Abandon | 23 | 3 | 0 | No | No |
| 18105758 | SIMPLE FIXATION AND STABILISATION | February 2023 | October 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18040418 | Method To Sense the Presence and Activity of Microbes Through the Use of Transient Sensing Materials | February 2023 | December 2024 | Allow | 22 | 2 | 1 | No | No |
| 18099786 | MICROFLUIDIC DEVICE, SYSTEM, AND METHOD FOR THE STUDY OF ORGANISMS | January 2023 | February 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18054364 | METHODS TO IMPROVE CELL THERAPY | November 2022 | June 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18051360 | Therapeutic Drug Monitoring | October 2022 | June 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17954128 | METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS | September 2022 | January 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17948541 | METHODS AND DEVICES FOR HIGH THROUGHPUT PURIFICATION | September 2022 | May 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17908507 | METHOD FOR THE HYDROXYLATION OF STEROIDS | August 2022 | January 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17896539 | COMPOSITIONS AND METHODS FOR TRANSPLANTATION OF COLON MICROBIOTA | August 2022 | May 2024 | Abandon | 20 | 2 | 1 | No | No |
| 17881175 | IMMOBILIZED ENZYMATIC REACTOR | August 2022 | October 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17866455 | Synell Creation, Evolution, And Digital Transmission | July 2022 | March 2025 | Allow | 32 | 1 | 1 | No | No |
| 17863778 | ADMINISTRATION AND MONITORING OF NITRIC OXIDE IN EX VIVO FLUIDS | July 2022 | April 2024 | Allow | 21 | 1 | 1 | No | No |
| 17863119 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER USING BOTULINUM TOXIN A | July 2022 | May 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17812148 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | July 2022 | August 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17856266 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | July 2022 | January 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17852951 | FORMULATIONS FOR DRYING BACTERIAL CELL EXTRACTS | June 2022 | May 2024 | Allow | 23 | 0 | 0 | Yes | No |
| 17852314 | COMPOSITIONS AND METHODS FOR TRANSPLANTATION OF COLON MICROBIOTA | June 2022 | August 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17750908 | CULTURE MEDIUM COMPOSITION AND METHOD OF CULTURING CELL OR TISSUE USING THEREOF | May 2022 | March 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17778958 | Methods and Compositions for Enzymatic Polymerization of N3` -> P5` Phosphoramidate DNA | May 2022 | June 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17749694 | USE OF L. REUTERI FOR RECOVERY OF MICROBIOTA DYSBIOSIS IN EARLY LIFE | May 2022 | April 2023 | Allow | 11 | 1 | 0 | No | No |
| 17729644 | TREATMENT RESPONSE ASSESSMENT USING NORMALIZED SINGLE CELL MEASUREMENTS | April 2022 | May 2024 | Allow | 25 | 4 | 1 | No | No |
| 17702276 | PREPARATION OF BIOLOGICAL CELLS ON MASS SPECTROMETRIC SAMPLE SUPPORTS FOR DESORBING IONIZATION | March 2022 | January 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17761053 | IMPROVED THERMOSTABLE VIRAL REVERSE TRANSCRIPTASE | March 2022 | May 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17688115 | DEVICE AND METHOD FOR CONTROLLING A BIOREACTOR | March 2022 | March 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17645507 | BIOLOGICALS AND THEIR USE IN PLANTS | December 2021 | November 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17558094 | COMPOSITIONS AND METHODS FOR TRANSPLANTATION OF COLON MICROBIOTA | December 2021 | January 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17523216 | APPARATUS AND METHOD FOR CELL, SPORE, OR VIRUS CAPTURE AND DISRUPTION | November 2021 | September 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17513568 | Method for the Direct Detection and/or Quantification of at Least One Compound with a Molecular Weight of at Least 200 | October 2021 | July 2024 | Allow | 33 | 1 | 1 | No | No |
| 17512975 | NOVEL ENZYMATIC METHODS TO GENERATE HIGH YIELDS OF SEQUENCE SPECIFIC RNAS WITH EXTREME PRECISION | October 2021 | June 2025 | Allow | 43 | 0 | 1 | No | No |
| 17489627 | APPARATUS AND METHOD FOR CELL, SPORE, OR VIRUS CAPTURE AND DISRUPTION | September 2021 | September 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17471698 | PROCESS FOR MANUFACTURING YEAST STRAINS HAVING INCREASED MANNAN OLIGOSACCHARIDES AND IMPROVED AMINO ACID PROFILES | September 2021 | August 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17405491 | STABLE PHARMACEUTICAL FOAM | August 2021 | December 2023 | Allow | 27 | 2 | 1 | No | No |
| 17405113 | BONE GRAFTS INCLUDING OSTEOGENIC STEM CELLS, AND METHODS RELATING TO THE SAME | August 2021 | May 2023 | Allow | 21 | 1 | 0 | No | No |
| 17398695 | USE OF A GLOBAL ASSAY OF COAGULATION AND FIBRINOLYSIS TO AIDE IN THROMBOEMBOLISM | August 2021 | August 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17426178 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS AND OTHER CONDITIONS CAUSED BY GUT MICROBIAL DYSBIOSIS | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17359526 | PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY PROFILING OF UNIDENTIFIED PATHOGENS DIRECTLY FROM PATIENT SAMPLES | June 2021 | January 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17351322 | Method for Processing Oil Crops with Rhodotorula | June 2021 | February 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17346411 | SYSTEMS AND METHODS FOR PRODUCING A SUGAR STREAM | June 2021 | October 2022 | Allow | 17 | 1 | 1 | No | No |
| 17346412 | SYSTEMS AND METHODS FOR PRODUCING A SUGAR STREAM | June 2021 | March 2022 | Allow | 9 | 1 | 0 | No | No |
| 17299375 | RECOMBINANT VECTOR CONTAINING IMMUNOGENIC PROTEIN OF AFRICAN SWINE FEVER VIRUS, RECOMBINANT BACTERIA AND USE THEREOF | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17299018 | FLUOROGENIC NUCLEIC ACID MOLECULE AND TARGET RNA FLUORESCENT LABELING METHOD | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17309488 | METHOD FOR SYNTHESIZING SINGLE-STRANDED DNA | June 2021 | December 2024 | Allow | 42 | 1 | 1 | No | No |
| 17328879 | METHOD AND REAGENT FOR QUANTIFYING CHOLESTEROL IN HIGH DENSITY LIPOPROTEIN 3 | May 2021 | May 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17328329 | DEBRANCHING ENZYME MODIFIED STARCH, THE PREPARING METHOD AND USE THEREOF IN HARD CAPSULE PRODUCTION | May 2021 | April 2023 | Allow | 23 | 1 | 0 | No | No |
| 17292400 | METHOD FOR SEQUENCING POLYNUCLEOTIDES | May 2021 | April 2025 | Allow | 47 | 1 | 1 | No | No |
| 17307962 | CELL CULTURE LASER PHOTOABLATION | May 2021 | August 2023 | Allow | 27 | 1 | 0 | No | No |
| 17285989 | RNA MEDIATED GENE REGULATING METHODS | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17203015 | System and Parametric Method for Cancer Discriminations | March 2021 | February 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17194148 | METHODS OF PRODUCING FUNCTIONALIZED POWDER PARTICLES | March 2021 | April 2024 | Allow | 38 | 1 | 1 | No | No |
| 17271982 | COMPOSITIONS AND METHODS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN HUMAN ANGELMAN SYNDROME | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17176365 | SACCHAROMYCES CEREVISIAE KWON P-1, 2, 3 WHICH PRODUCE ALDEHYDE DEHYDROGENASE AND GLUTATHIONE | February 2021 | October 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17166108 | PROTEIN FORMULATIONS | February 2021 | November 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17159614 | PROCESS FOR CONTROLLING ORGANIC ACID RATIOS IN A CARBON DIOXIDE BIOCONVERSION PROCESS | January 2021 | February 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17247771 | PROCESS FOR MANUFACTURING YEAST STRAINS HAVING INCREASED MANNAN OLIGOSACCHARIDES AND IMPROVED AMINO ACID PROFILES | December 2020 | August 2021 | Allow | 8 | 2 | 1 | No | No |
| 17253929 | VECTORS FOR GENE DELIVERY THAT PERSIST WITHIN CELLS | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17251125 | ASPERGILLUS ORYZAE BLCY-006 STRAIN AND APPLICATION THEREOF IN PREPARATION OF GALACTOOLIGOSACCHARIDE | December 2020 | January 2022 | Allow | 13 | 1 | 0 | No | No |
| 16972709 | INTERLEUKIN-6, 10 PRODUCTION PROMOTER | December 2020 | June 2023 | Allow | 30 | 5 | 0 | Yes | No |
| 16972983 | METHODS OF PROTECTING A PLANT FROM A FUNGAL PEST | December 2020 | April 2024 | Allow | 41 | 2 | 1 | No | No |
| 17051631 | METHOD FOR PREPARING SOLID-STATE PHOTONIC CRYSTAL IPN COMPOSITE FUNCTIONALIZED WITH ENZYME, PHOTONIC CRYSTAL IPN COMPOSITE PREPARED BY THE METHOD AND BIOSENSOR USING THE PHOTONIC CRYSTAL IPN COMPOSITE | October 2020 | November 2023 | Allow | 36 | 0 | 1 | No | No |
| 17063810 | SYSTEM AND METHOD FOR DETECTING A TARGET ENZYME | October 2020 | May 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17041947 | ADENOSINE-HIGH PRODUCTION PAECILOMYCES HEPIALI CS4 STRAIN ISOLATED FROM CORDYCEPS SINENSIS | September 2020 | February 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17040317 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | September 2020 | March 2025 | Allow | 54 | 1 | 1 | No | No |
| 17013359 | Dimeric Antigen Receptors | September 2020 | August 2024 | Allow | 47 | 1 | 1 | No | No |
| 16977950 | MICROBIOLOGICAL MEDIA AND METHODS OF USING SAME | September 2020 | March 2023 | Allow | 30 | 2 | 1 | No | No |
| 17004970 | SYSTEMS AND METHODS FOR CULTURING EPITHELIAL CELLS | August 2020 | May 2023 | Allow | 33 | 1 | 1 | No | No |
| 16975933 | IRF-4 ENGINEERED T CELLS AND USES THEREOF IN TREATING CANCER | August 2020 | June 2024 | Allow | 46 | 1 | 1 | No | No |
| 16989886 | Diabetes Control Using Postprandial Feedback | August 2020 | August 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16990833 | FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | August 2020 | January 2021 | Allow | 5 | 0 | 1 | No | No |
| 16990857 | FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | August 2020 | August 2024 | Allow | 48 | 2 | 1 | No | No |
| 16990841 | FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | August 2020 | December 2020 | Allow | 5 | 0 | 1 | No | No |
| 16967117 | CODON OPTIMIZED PRECURSOR GENE AND SIGNAL PEPTIDE GENE OF HUMAN INSULIN ANALOGUE | August 2020 | March 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16962474 | SCREENING METHOD | July 2020 | October 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16928620 | System and Parametric Method for Cancer Discriminations | July 2020 | February 2021 | Allow | 7 | 1 | 1 | No | No |
| 16961799 | FIBRINOGEN TEST | July 2020 | April 2025 | Abandon | 57 | 3 | 1 | No | Yes |
| 16957905 | FETAL TISSUE EXTRACT, METHODS FOR PRODUCING THE EXTRACT, AND THE USE THEREOF | June 2020 | July 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16770324 | USE OF A GLOBAL ASSAY OF COAGULATION AND FIBRINOLYSIS TO AIDE IN THROMBOEMBOLISM | June 2020 | January 2022 | Abandon | 19 | 1 | 1 | No | No |
| 16893358 | Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapy | June 2020 | August 2023 | Allow | 39 | 1 | 1 | No | No |
| 16764490 | IMMUNOISOLATION DEVICE | May 2020 | April 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16875775 | METHODS FOR MEASURING REDUCING EQUIVALENT PRODUCTION BY TISSUES TO DETERMINE METABOLIC RATES AND METHODS OF USE | May 2020 | January 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16856632 | ADMINISTRATION AND MONITORING OF NITRIC OXIDE IN EX VIVO FLUIDS | April 2020 | April 2022 | Allow | 24 | 1 | 0 | No | No |
| 16755854 | METHOD FOR PREPARING PROTEIN PEPTIDE BASED ON CONNECTIVE TISSUE AND PREPARED PROTEIN PEPTIDE AND USE THEREOF | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16841770 | MEANS AND METHODS FOR VITAMIN B12 PRODUCTION IN DUCKWEED | April 2020 | May 2021 | Abandon | 13 | 2 | 0 | No | No |
| 16841307 | FORMULATIONS FOR DRYING BACTERIAL CELL EXTRACTS | April 2020 | March 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16462973 | COMPOSITION FOR BIOTISSUE CLEARING AND BIOTISSUE CLEARING METHOD USING SAME | April 2020 | March 2023 | Allow | 46 | 1 | 1 | Yes | No |
| 16829329 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | March 2020 | March 2022 | Allow | 23 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YAMASAKI, ROBERT J.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 45.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner YAMASAKI, ROBERT J works in Art Unit 1657 and has examined 584 patent applications in our dataset. With an allowance rate of 66.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner YAMASAKI, ROBERT J's allowance rate of 66.1% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by YAMASAKI, ROBERT J receive 2.07 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by YAMASAKI, ROBERT J is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.4% benefit to allowance rate for applications examined by YAMASAKI, ROBERT J. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.8% of applications are subsequently allowed. This success rate is in the 35% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 21.6% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 140.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 87% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 89.3% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 72.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 48.1% are granted (fully or in part). This grant rate is in the 56% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.